Renal denervation, the once-promising treatment for high blood pressure, has fizzled out after a failed trial from Medtronic.
JNJ's European approval for a renal denervation device was unexpected, but more work needs to be done.
Bard has significantly improved its growth outlook, but Wall Street seems a step or two ahead.
Hypertension treatment renal denervation has been a hot topic in the medical device industry, but a recent trial disappointment from Medtronic has companies like Covidien and Boston Scientific backpedaling.
Renal denervation's a huge opportunity for Medtronic, St. Jude Medical, and other leading device companies, but recent setbacks have investors wondering how long it will be before potential translates into results
A potential $3 billion/year therapy may not work nearly as well as hoped.
What is the outlook for AngioDynamics, DexCom, and Abiomed?
Boston Scientific is cutting costs in a bid to return to profitability. So, why did the company spend $275 million to acquire the electrophysiology business from competitor C.R. Bard?
With its solid business, Baxter International is a stock to watch for investors looking for dividends.
This company's struggling with declining sales, but renal denervation offers a long-term hope for St. Jude's future.